nach oben

Cancer and Metastasis Reviews

Erschienen in:

15.04.2023 | Non-Thematic Review

Colorectal cancer liver metastasis: genomic evolution and crosstalk with the liver microenvironment

verfasst von: Qiu-Luo Liu, Huijie Zhou, Zong-Guang Zhou, Hai-Ning Chen

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 2/2023

Einloggen, um Zugang zu erhalten

Abstract

Colorectal cancer (CRC) patients frequently develop liver metastases, which are the major cause of cancer-related mortality. The molecular basis and management of colorectal liver metastases (CRLMs) remain a challenging clinical issue. Recent genomic evidence has demonstrated the liver tropism of CRC and the presence of a stricter evolutionary bottleneck in the liver as a target organ compared to lymph nodes. This bottleneck challenging CRC cells in the liver is organ-specific and requires adaptation not only at the genetic level, but also at the phenotypic level to crosstalk with the hepatic microenvironment. Here, we highlight the emerging evidence on the clonal evolution of CRLM and review recent insights into the molecular mechanisms orchestrating the bidirectional interactions between metastatic CRC cells and the unique liver microenvironment.

Biller, L. H., & Schrag, D. (2021). Diagnosis and treatment of metastatic colorectal cancer: A review. JAMA, 325(7), 669–685. https://doi.org/10.1001/jama.2021.0106CrossRefPubMed

Dekker, E., Tanis, P. J., Vleugels, J. L. A., Kasi, P. M., & Wallace, M. B. (2019). Colorectal cancer. Lancet, 394(10207), 1467–1480. https://doi.org/10.1016/S0140-6736(19)32319-0CrossRefPubMed

Tsilimigras, D. I., Brodt, P., Clavien, P. A., Muschel, R. J., D'Angelica, M. I., Endo, I., et al. (2021). Liver metastases. Nature Reviews Disease Primers, 7(1), 27. https://doi.org/10.1038/s41572-021-00261-6CrossRefPubMed

Milette, S., Sicklick, J. K., Lowy, A. M., & Brodt, P. (2017). Molecular pathways: Targeting the Microenvironment of liver metastases. Clinical Cancer Research, 23(21), 6390–6399. https://doi.org/10.1158/1078-0432.CCR-15-1636CrossRefPubMedPubMedCentral

Hess, K. R., Varadhachary, G. R., Taylor, S. H., Wei, W., Raber, M. N., Lenzi, R., et al. (2006). Metastatic patterns in adenocarcinoma. Cancer, 106(7), 1624–1633. https://doi.org/10.1002/cncr.21778CrossRefPubMed

Paget, S. (1989). The distribution of secondary growths in cancer of the breast. The Lancet, 8(2), 98–101.

Chow, F. C., & Chok, K. S. (2019). Colorectal liver metastases: An update on multidisciplinary approach. World Journal of Hepatology, 11(2), 150–172. https://doi.org/10.4254/wjh.v11.i2.150CrossRefPubMedPubMedCentral

Vidal-Vanaclocha, F. (2008). The prometastatic microenvironment of the liver. Cancer Microenviron, 1(1), 113–129. https://doi.org/10.1007/s12307-008-0011-6CrossRefPubMedPubMedCentral

Mielgo, A., & Schmid, M. C. (2020). Liver tropism in cancer: The hepatic metastatic niche. Cold Spring Harbor Perspectives in Medicine, 10(3), a037259. https://doi.org/10.1101/cshperspect.a037259CrossRefPubMedPubMedCentral

10.

Poisson, J., Lemoinne, S., Boulanger, C., Durand, F., Moreau, R., Valla, D., et al. (2017). Liver sinusoidal endothelial cells: Physiology and role in liver diseases. Journal of Hepatology, 66(1), 212–227. https://doi.org/10.1016/j.jhep.2016.07.009CrossRefPubMed

11.

Miskovic, D., & Mirnezami, R. (2021). Is complete mesocolic excision superior to conventional colectomy for colon cancer? Lancet Oncology, 22(7), 917–918. https://doi.org/10.1016/S1470-2045(21)00256-4CrossRefPubMed

12.

Fujita, S., Mizusawa, J., Kanemitsu, Y., Ito, M., Kinugasa, Y., Komori, K., et al. (2017). Mesorectal excision with or without lateral lymph node dissection for clinical stage II/III lower rectal cancer (JCOG0212): A multicenter, randomized controlled, noninferiority trial. Annals of Surgery, 266(2), 201–207. https://doi.org/10.1097/SLA.0000000000002212CrossRefPubMed

13.

Markowitz, S. D. (2017). Cancer bypasses the lymph nodes. Science, 357(6346), 35–36. https://doi.org/10.1126/science.aan8299CrossRefPubMed

14.

Siravegna, G., Lazzari, L., Crisafulli, G., Sartore-Bianchi, A., Mussolin, B., Cassingena, A., et al. (2018). Radiologic and genomic evolution of individual metastases during HER2 blockade in colorectal cancer. Cancer Cell, 34(1), 148–162. https://doi.org/10.1016/j.ccell.2018.06.004CrossRefPubMed

15.

Russo, M., Siravegna, G., Blaszkowsky, L. S., Corti, G., Crisafulli, G., Ahronian, L. G., et al. (2016). Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer. Cancer Discovery, 6(2), 147–153. https://doi.org/10.1158/2159-8290.CD-15-1283CrossRefPubMed

16.

Pietrantonio, F., Oddo, D., Gloghini, A., Valtorta, E., Berenato, R., Barault, L., et al. (2016). MET-driven resistance to dual EGFR and BRAF blockade may be overcome by switching from EGFR to MET inhibition in BRAF-mutated colorectal cancer. Cancer Discovery, 6(9), 963–971. https://doi.org/10.1158/2159-8290.CD-16-0297CrossRefPubMed

17.

Ryser, M. D., Mallo, D., Hall, A., Hardman, T., King, L. M., Tatishchev, S., et al. (2020). Minimal barriers to invasion during human colorectal tumor growth. Nature Communications, 11(1), 1280. https://doi.org/10.1038/s41467-020-14908-7CrossRefPubMedPubMedCentral

18.

Hu, Z., Li, Z., Ma, Z., & Curtis, C. (2020). Multi-cancer analysis of clonality and the timing of systemic spread in paired primary tumors and metastases. Nature Genetics, 52(7), 701–708. https://doi.org/10.1038/s41588-020-0628-zCrossRefPubMedPubMedCentral

19.

Naxerova, K., Reiter, J. G., Brachtel, E., Lennerz, J. K., van de Wetering, M., Rowan, A., et al. (2017). Origins of lymphatic and distant metastases in human colorectal cancer. Science, 357(6346), 55–60. https://doi.org/10.1126/science.aai8515CrossRefPubMedPubMedCentral

20.

Househam, J., Heide, T., Cresswell, G. D., Spiteri, I., Kimberley, C., Zapata, L., et al. (2022). Phenotypic plasticity and genetic control in colorectal cancer evolution. Nature, 611(7937), 744–753. https://doi.org/10.1038/s41586-022-05311-xCrossRefPubMedPubMedCentral

21.

Wu, Y., Yang, S., Ma, J., Chen, Z., Song, G., Rao, D., et al. (2021). Spatiotemporal immune landscape of colorectal cancer liver metastasis at single-cell level. Cancer Discovery, 12(1), 134–153. https://doi.org/10.1158/2159-8290.CD-21-0316CrossRefPubMed

22.

Li, C., Sun, Y. D., Yu, G. Y., Cui, J. R., Lou, Z., Zhang, H., et al. (2020). Integrated omics of metastatic colorectal cancer. Cancer Cell, 38(5), 734–747 e739. https://doi.org/10.1016/j.ccell.2020.08.002CrossRefPubMed

23.

Liu, Y., Zhang, Q., Xing, B., Luo, N., Gao, R., Yu, K., et al. (2022). Immune phenotypic linkage between colorectal cancer and liver metastasis. Cancer Cell, 40(4), 424–437. https://doi.org/10.1016/j.ccell.2022.02.013CrossRefPubMed

24.

Obenauf, A. C., & Massague, J. (2015). Surviving at a distance: Organ-specific metastasis. Trends in Cancer, 1(1), 76–91. https://doi.org/10.1016/j.trecan.2015.07.009CrossRefPubMedPubMedCentral

25.

Wei, Q., Ye, Z., Zhong, X., Li, L., Wang, C., Myers, R. E., et al. (2017). Multiregion whole-exome sequencing of matched primary and metastatic tumors revealed genomic heterogeneity and suggested polyclonal seeding in colorectal cancer metastasis. Annals of Oncology, 28(9), 2135–2141. https://doi.org/10.1093/annonc/mdx278CrossRefPubMedPubMedCentral

26.

Dang, H. X., Krasnick, B. A., White, B. S., Grossman, J. G., Strand, M. S., Zhang, J., et al. (2020). The clonal evolution of metastatic colorectal cancer. Science Advances, 6(24), eaay9691. https://doi.org/10.1126/sciadv.aay9691CrossRefPubMedPubMedCentral

27.

Alves, J. M., Prado-Lopez, S., Cameselle-Teijeiro, J. M., & Posada, D. (2019). Rapid evolution and biogeographic spread in a colorectal cancer. Nature Communications, 10(1), 5139. https://doi.org/10.1038/s41467-019-12926-8CrossRefPubMedPubMedCentral

28.

Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., et al. (2010). Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature, 467(7319), 1114–1117. https://doi.org/10.1038/nature09515CrossRefPubMedPubMedCentral

29.

Campbell, P. J., Yachida, S., Mudie, L. J., Stephens, P. J., Pleasance, E. D., Stebbings, L. A., et al. (2010). The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature, 467(7319), 1109–1113. https://doi.org/10.1038/nature09460CrossRefPubMedPubMedCentral

30.

Turajlic, S., & Swanton, C. (2016). Metastasis as an evolutionary process. Science, 352(6282), 169–175. https://doi.org/10.1126/science.aaf2784CrossRefPubMed

31.

Turajlic, S., Furney, S. J., Lambros, M. B., Mitsopoulos, C., Kozarewa, I., Geyer, F. C., et al. (2012). Whole genome sequencing of matched primary and metastatic acral melanomas. Genome Research, 22(2), 196–207. https://doi.org/10.1101/gr.125591.111CrossRefPubMedPubMedCentral

32.

Gundem, G., Van Loo, P., Kremeyer, B., Alexandrov, L. B., Tubio, J. M. C., Papaemmanuil, E., et al. (2015). The evolutionary history of lethal metastatic prostate cancer. Nature, 520(7547), 353–357. https://doi.org/10.1038/nature14347CrossRefPubMedPubMedCentral

33.

Gkountela, S., Castro-Giner, F., Szczerba, B. M., Vetter, M., Landin, J., Scherrer, R., et al. (2019). Circulating tumor cell clustering shapes DNA methylation to enable metastasis seeding. Cell, 176(1-2), 98–112. https://doi.org/10.1016/j.cell.2018.11.046CrossRefPubMedPubMedCentral

34.

Aceto, N., Bardia, A., Miyamoto, D. T., Donaldson, M. C., Wittner, B. S., Spencer, J. A., et al. (2014). Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell, 158(5), 1110–1122. https://doi.org/10.1016/j.cell.2014.07.013CrossRefPubMedPubMedCentral

35.

Reiter, J. G., Hung, W. T., Lee, I. H., Nagpal, S., Giunta, P., Degner, S., et al. (2020). Lymph node metastases develop through a wider evolutionary bottleneck than distant metastases. Nature Genetics, 52(7), 692–700. https://doi.org/10.1038/s41588-020-0633-2CrossRefPubMedPubMedCentral

36.

Priestley, P., Baber, J., Lolkema, M. P., Steeghs, N., de Bruijn, E., Shale, C., et al. (2019). Pan-cancer whole-genome analyses of metastatic solid tumours. Nature, 575(7781), 210–216. https://doi.org/10.1038/s41586-019-1689-yCrossRefPubMedPubMedCentral

37.

Bian, S., Hou, Y., Zhou, X., Li, X., Yong, J., Wang, Y., et al. (2018). Single-cell multiomics sequencing and analyses of human colorectal cancer. Science, 362(6418), 1060–1063. https://doi.org/10.1126/science.aao3791CrossRefPubMed

38.

Reiter, J. G., Makohon-Moore, A. P., Gerold, J. M., Heyde, A., Attiyeh, M. A., Kohutek, Z. A., et al. (2018). Minimal functional driver gene heterogeneity among untreated metastases. Science, 361(6406), 1033–1037. https://doi.org/10.1126/science.aat7171CrossRefPubMedPubMedCentral

39.

Chen, H. N., Shu, Y., Liao, F., Liao, X., Zhang, H., Qin, Y., et al. (2021). Genomic evolution and diverse models of systemic metastases in colorectal cancer. Gut, 71(2), 322–332. https://doi.org/10.1136/gutjnl-2020-323703CrossRefPubMed

40.

Ishaque, N., Abba, M. L., Hauser, C., Patil, N., Paramasivam, N., Huebschmann, D., et al. (2018). Whole genome sequencing puts forward hypotheses on metastasis evolution and therapy in colorectal cancer. Nature Communications, 9(1), 4782. https://doi.org/10.1038/s41467-018-07041-zCrossRefPubMedPubMedCentral

41.

Alves, J. M., Prado-Lopez, S., Tomas, L., Valecha, M., Estevez-Gomez, N., Alvarino, P., et al. (2022). Clonality and timing of relapsing colorectal cancer metastasis revealed through whole-genome single-cell sequencing. Cancer Letters, 543, 215767. https://doi.org/10.1016/j.canlet.2022.215767CrossRefPubMed

42.

van de Haar, J., Hoes, L. R., Roepman, P., Lolkema, M. P., Verheul, H. M. W., Gelderblom, H., et al. (2021). Limited evolution of the actionable metastatic cancer genome under therapeutic pressure. Nature Medicine, 27(9), 1553–1563. https://doi.org/10.1038/s41591-021-01448-wCrossRefPubMed

43.

Ahronian, L. G., Sennott, E. M., Van Allen, E. M., Wagle, N., Kwak, E. L., Faris, J. E., et al. (2015). Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant colorectal cancer through MAPK pathway alterations. Cancer Discovery, 5(4), 358–367. https://doi.org/10.1158/2159-8290.CD-14-1518CrossRefPubMedPubMedCentral

44.

Bertotti, A., Papp, E., Jones, S., Adleff, V., Anagnostou, V., Lupo, B., et al. (2015). The genomic landscape of response to EGFR blockade in colorectal cancer. Nature, 526(7572), 263–267. https://doi.org/10.1038/nature14969CrossRefPubMedPubMedCentral

45.

Missiaglia, E., Jacobs, B., D'Ario, G., Di Narzo, A. F., Soneson, C., Budinska, E., et al. (2014). Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Annals of Oncology, 25(10), 1995–2001. https://doi.org/10.1093/annonc/mdu275CrossRefPubMed

46.

Amri, R., Bordeianou, L. G., Sylla, P., & Berger, D. L. (2015). Variations in metastasis site by primary location in colon cancer. Journal of Gastrointestinal Surgery, 19(8), 1522–1527. https://doi.org/10.1007/s11605-015-2837-9CrossRefPubMed

47.

Riihimaki, M., Hemminki, A., Sundquist, J., & Hemminki, K. (2016). Patterns of metastasis in colon and rectal cancer. Science Reporter, 6, 29765. https://doi.org/10.1038/srep29765CrossRef

48.

Russolillo, N., Sperti, E., Langella, S., Menonna, F., Allieta, A., Di Maio, M., et al. (2020). Impact of primary tumor location on patterns of recurrence and survival of patients undergoing resection of liver metastases from colon cancer. HPB (Oxford), 22(1), 116–123. https://doi.org/10.1016/j.hpb.2019.05.014CrossRefPubMed

49.

Engstrand, J., Nilsson, H., Stromberg, C., Jonas, E., & Freedman, J. (2018). Colorectal cancer liver metastases - a population-based study on incidence, management and survival. BMC Cancer, 18(1), 78. https://doi.org/10.1186/s12885-017-3925-xCrossRefPubMedPubMedCentral

50.

Yaeger, R., Chatila, W. K., Lipsyc, M. D., Hechtman, J. F., Cercek, A., Sanchez-Vega, F., et al. (2018). Clinical sequencing defines the genomic landscape of metastatic colorectal cancer. Cancer Cell, 33(1), 125–136. https://doi.org/10.1016/j.ccell.2017.12.004CrossRefPubMedPubMedCentral

51.

Kim, S. C., Park, J. W., Seo, H. Y., Kim, M., Park, J. H., Kim, G. H., et al. (2022). Multifocal organoid capturing of colon cancer reveals pervasive intratumoral heterogenous drug responses. Advanced Sciencev (Weinh), 9(5), e2103360. https://doi.org/10.1002/advs.202103360CrossRef

52.

Banerjee, S., Zhang, X., Kuang, S., Wang, J., Li, L., Fan, G., et al. (2021). Comparative analysis of clonal evolution among patients with right- and left-sided colon and rectal cancer. Iscience, 24(7), 102718. https://doi.org/10.1016/j.isci.2021.102718CrossRefPubMedPubMedCentral

53.

Sobral, D., Martins, M., Kaplan, S., Golkaram, M., Salmans, M., Khan, N., et al. (2022). Genetic and microenvironmental intra-tumor heterogeneity impacts colorectal cancer evolution and metastatic development. Communications Biology, 5(1), 937. https://doi.org/10.1038/s42003-022-03884-xCrossRefPubMedPubMedCentral

54.

Joung, J. G., Oh, B. Y., Hong, H. K., Al-Khalidi, H., Al-Alem, F., Lee, H. O., et al. (2017). Tumor heterogeneity predicts metastatic potential in colorectal cancer. Clinical Cancer Research, 23(23), 7209–7216. https://doi.org/10.1158/1078-0432.CCR-17-0306CrossRefPubMed

55.

Malesci, A., Laghi, L., Bianchi, P., Delconte, G., Randolph, A., Torri, V., et al. (2007). Reduced likelihood of metastases in patients with microsatellite-unstable colorectal cancer. Clinical Cancer Research, 13(13), 3831–3839. https://doi.org/10.1158/1078-0432.CCR-07-0366CrossRefPubMed

56.

Li, X., Ramadori, P., Pfister, D., Seehawer, M., Zender, L., & Heikenwalder, M. (2021). The immunological and metabolic landscape in primary and metastatic liver cancer. Nature Reviews Cancer, 21(9), 541–557. https://doi.org/10.1038/s41568-021-00383-9CrossRefPubMed

57.

Berndt, N., Kolbe, E., Gajowski, R., Eckstein, J., Ott, F., Meierhofer, D., et al. (2021). Functional consequences of metabolic zonation in murine livers: Insights for an old Story. Hepatology, 73(2), 795–810. https://doi.org/10.1002/hep.31274CrossRefPubMed

58.

Bergers, G., & Fendt, S. M. (2021). The metabolism of cancer cells during metastasis. Nature Reviews Cancer, 21(3), 162–180. https://doi.org/10.1038/s41568-020-00320-2CrossRefPubMedPubMedCentral

59.

Bu, P., Chen, K. Y., Xiang, K., Johnson, C., Crown, S. B., Rakhilin, N., et al. (2018). Aldolase B-mediated fructose metabolism drives metabolic reprogramming of colon cancer liver metastasis. Cell Metabolism, 27(6), 1249–1262. https://doi.org/10.1016/j.cmet.2018.04.003CrossRefPubMedPubMedCentral

60.

Loo, J. M., Scherl, A., Nguyen, A., Man, F. Y., Weinberg, E., Zeng, Z., et al. (2015). Extracellular metabolic energetics can promote cancer progression. Cell, 160(3), 393–406. https://doi.org/10.1016/j.cell.2014.12.018CrossRefPubMedPubMedCentral

61.

Garcia-Bermudez, J., Baudrier, L., La, K., Zhu, X. G., Fidelin, J., Sviderskiy, V. O., et al. (2018). Aspartate is a limiting metabolite for cancer cell proliferation under hypoxia and in tumours. Nature Cell Biology, 20(7), 775–781. https://doi.org/10.1038/s41556-018-0118-zCrossRefPubMedPubMedCentral

62.

Yamaguchi, N., Weinberg, E. M., Nguyen, A., Liberti, M. V., Goodarzi, H., Janjigian, Y. Y., et al. (2019). PCK1 and DHODH drive colorectal cancer liver metastatic colonization and hypoxic growth by promoting nucleotide synthesis. Elife, 8, e52135. https://doi.org/10.7554/eLife.52135CrossRefPubMedPubMedCentral

63.

Wang, K., Jiang, J., Lei, Y., Zhou, S., Wei, Y., & Huang, C. (2019). Targeting metabolic-redox circuits for cancer therapy. Trends in Biochemical Sciences, 44(5), 401–414. https://doi.org/10.1016/j.tibs.2019.01.001CrossRefPubMed

64.

Gao, W., Chen, L., Ma, Z., Du, Z., Zhao, Z., Hu, Z., et al. (2013). Isolation and phenotypic characterization of colorectal cancer stem cells with organ-specific metastatic potential. Gastroenterology, 145(3), 636–646. https://doi.org/10.1053/j.gastro.2013.05.049CrossRefPubMed

65.

Wu, Z., Wei, D., Gao, W., Xu, Y., Hu, Z., Ma, Z., et al. (2015). TPO-induced metabolic reprogramming drives liver metastasis of colorectal cancer CD110+ tumor-initiating Cells. Cell Stem Cell, 17(1), 47–59. https://doi.org/10.1016/j.stem.2015.05.016CrossRefPubMed

66.

Nguyen, A., Loo, J. M., Mital, R., Weinberg, E. M., Man, F. Y., Zeng, Z., et al. (2016). PKLR promotes colorectal cancer liver colonization through induction of glutathione synthesis. The Journal of Clinical Investigation, 126(2), 681–694. https://doi.org/10.1172/JCI83587CrossRefPubMedPubMedCentral

67.

Anastasiou, D., Poulogiannis, G., Asara, J. M., Boxer, M. B., Jiang, J. K., Shen, M., et al. (2011). Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science, 334(6060), 1278–1283. https://doi.org/10.1126/science.1211485CrossRefPubMedPubMedCentral

68.

Heymann, F., & Tacke, F. (2016). Immunology in the liver--from homeostasis to disease. Nature Reviews. Gastroenterology & Hepatology, 13(2), 88–110. https://doi.org/10.1038/nrgastro.2015.200CrossRef

69.

Crispe, I. N. (2014). Immune tolerance in liver disease. Hepatology, 60(6), 2109–2117. https://doi.org/10.1002/hep.27254CrossRefPubMed

70.

O'Leary, K. (2021). Liver metastases cultivate an immune desert. Nature Reviews. Cancer, 21(3), 143. https://doi.org/10.1038/s41568-021-00338-0CrossRefPubMed

71.

Canellas-Socias, A., Cortina, C., Hernando-Momblona, X., Palomo-Ponce, S., Mulholland, E. J., Turon, G., et al. (2022). Metastatic recurrence in colorectal cancer arises from residual EMP1(+) cells. Nature, 611(7936), 603–613. https://doi.org/10.1038/s41586-022-05402-9CrossRefPubMed

72.

Yu, J., Green, M. D., Li, S., Sun, Y., Journey, S. N., Choi, J. E., et al. (2021). Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. Nature Medicine, 27(1), 152–164. https://doi.org/10.1038/s41591-020-1131-xCrossRefPubMedPubMedCentral

73.

Song, J., Song, H., Wei, H., Sun, R., Tian, Z., & Peng, H. (2022). Requirement of RORalpha for maintenance and antitumor immunity of liver-resident natural killer cells/ILC1s. Hepatology, 75(5), 1181–1193. https://doi.org/10.1002/hep.32147CrossRefPubMed

74.

Tian, S., Chu, Y., Hu, J., Ding, X., Liu, Z., Fu, D., et al. (2022). Tumour-associated neutrophils secrete AGR2 to promote colorectal cancer metastasis via its receptor CD98hc-xCT. Gut, 71(12), 2489–2501. https://doi.org/10.1136/gutjnl-2021-325137CrossRefPubMed

75.

Wang, H., Zhang, B., Li, R., Chen, J., Xu, G., Zhu, Y., et al. (2022). KIAA1199 drives immune suppression to promote colorectal cancer liver metastasis by modulating neutrophil infiltration. Hepatology, 76(4), 967–981. https://doi.org/10.1002/hep.32383CrossRefPubMed

76.

Canellas-Socias, A., Cortina, C., Hernando-Momblona, X., Palomo-Ponce, S., Mulholland, E. J., Turon, G., et al. (2022). Metastatic recurrence in colorectal cancer arises from residual EMP1<sup>+</sup> cells. Nature, 611(7936), 603–613. https://doi.org/10.1038/s41586-022-05402-9CrossRefPubMed

77.

Gorelik, L., & Flavell, R. A. (2000). Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity, 12(2), 171–181. https://doi.org/10.1016/s1074-7613(00)80170-3CrossRefPubMed

78.

Tauriello, D. V. F., Palomo-Ponce, S., Stork, D., Berenguer-Llergo, A., Badia-Ramentol, J., Iglesias, M., et al. (2018). TGFbeta drives immune evasion in genetically reconstituted colon cancer metastasis. Nature, 554(7693), 538–543. https://doi.org/10.1038/nature25492CrossRefPubMed

79.

Ma, C., Han, M., Heinrich, B., Fu, Q., Zhang, Q., Sandhu, M., et al. (2018). Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. Science, 360(6391). https://doi.org/10.1126/science.aan5931

80.

Bertocchi, A., Carloni, S., Ravenda, P. S., Bertalot, G., Spadoni, I., Lo Cascio, A., et al. (2021). Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver. Cancer Cell, 39(5), 708–724. https://doi.org/10.1016/j.ccell.2021.03.004CrossRefPubMed

81.

Bullman, S., Pedamallu, C. S., Sicinska, E., Clancy, T. E., Zhang, X., Cai, D., et al. (2017). Analysis of fusobacterium persistence and antibiotic response in colorectal cancer. Science, 358(6369), 1443–1448. https://doi.org/10.1126/science.aal5240CrossRefPubMedPubMedCentral

82.

Spadoni, I., Zagato, E., Bertocchi, A., Paolinelli, R., Hot, E., Di Sabatino, A., et al. (2015). A gut-vascular barrier controls the systemic dissemination of bacteria. Science, 350(6262), 830–834. https://doi.org/10.1126/science.aad0135CrossRefPubMed

83.

Taieb, J., Svrcek, M., Cohen, R., Basile, D., Tougeron, D., & Phelip, J. M. (2022). Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment. European Journal of Cancer, 175, 136–157. https://doi.org/10.1016/j.ejca.2022.07.020CrossRefPubMed

84.

Testa, U., Castelli, G., & Pelosi, E. (2020). Genetic alterations of metastatic colorectal cancer. Biomedicines, 8(10), 414. https://doi.org/10.3390/biomedicines8100414CrossRefPubMedPubMedCentral

85.

Mouradov, D., Greenfield, P., Li, S., In, E. J., Storey, C., Sakthianandeswaren, A., et al. (2023). Onco-microbial community profiling identifies clinico-molecular and prognostic subtypes of colorectal cancer. Gastroenterology. https://doi.org/10.1053/j.gastro.2023.03.205

86.

Moreno, E., & Basler, K. (2004). dMyc transforms cells into super-competitors. Cell, 117(1), 117–129. https://doi.org/10.1016/s0092-8674(04)00262-4CrossRefPubMed

87.

Flanagan, D. J., Pentinmikko, N., Luopajarvi, K., Willis, N. J., Gilroy, K., Raven, A. P., et al. (2021). NOTUM from Apc-mutant cells biases clonal competition to initiate cancer. Nature, 594(7863), 430–435. https://doi.org/10.1038/s41586-021-03525-zCrossRefPubMed

88.

Kanada, M., Bachmann, M. H., & Contag, C. H. (2016). Signaling by extracellular vesicles advances cancer hallmarks. Trends in Cancer, 2(2), 84–94. https://doi.org/10.1016/j.trecan.2015.12.005CrossRefPubMed

89.

Moya, I. M., Castaldo, S. A., Van den Mooter, L., Soheily, S., Sansores-Garcia, L., Jacobs, J., et al. (2019). Peritumoral activation of the hippo pathway effectors YAP and TAZ suppresses liver cancer in mice. Science, 366(6468), 1029–1034. https://doi.org/10.1126/science.aaw9886CrossRefPubMed

90.

Lee, J. W., Stone, M. L., Porrett, P. M., Thomas, S. K., Komar, C. A., Li, J. H., et al. (2019). Hepatocytes direct the formation of a pro-metastatic niche in the liver. Nature, 567(7747), 249–252. https://doi.org/10.1038/s41586-019-1004-yCrossRefPubMedPubMedCentral

91.

Sethi, V., Kurtom, S., Tarique, M., Lavania, S., Malchiodi, Z., Hellmund, L., et al. (2018). Gut microbiota promotes tumor growth in mice by modulating immune response. Gastroenterology, 155(1), 33–37. https://doi.org/10.1053/j.gastro.2018.04.001CrossRefPubMed

92.

Bhattacharjee, S., Hamberger, F., Ravichandra, A., Miller, M., Nair, A., Affo, S., et al. (2021). Tumor restriction by type I collagen opposes tumor-promoting effects of cancer-associated fibroblasts. The Journal of Clinical Investigation, 131(11). https://doi.org/10.1172/JCI146987

93.

Biffi, G., & Tuveson, D. A. (2021). Diversity and biology of cancer-associated fibroblasts. Physiological Reviews, 101(1), 147–176. https://doi.org/10.1152/physrev.00048.2019CrossRefPubMed

94.

Barbazan, J., & Matic Vignjevic, D. (2019). Cancer associated fibroblasts: Is the force the path to the dark side? Current Opinion in Cell Biology, 56, 71–79. https://doi.org/10.1016/j.ceb.2018.09.002CrossRefPubMed

95.

Qi, M., Fan, S., Huang, M., Pan, J., Li, Y., Miao, Q., et al. (2022). Targeting FAPα-expressing hepatic stellate cells overcomes resistance to antiangiogenics in colorectal cancer liver metastasis models. The Journal of Clinical Investigation, 132. https://doi.org/10.1172/JCI157399

96.

Lampi, M. C., & Reinhart-King, C. A. (2018). Targeting extracellular matrix stiffness to attenuate disease: From molecular mechanisms to clinical trials. Science Translational Medicine, 10(422). https://doi.org/10.1126/scitranslmed.aao0475

97.

Kalli, M., & Stylianopoulos, T. (2018). Defining the role of solid stress and matrix stiffness in cancer cell proliferation and metastasis. Frontiers in Oncology, 8, 55. https://doi.org/10.3389/fonc.2018.00055CrossRefPubMedPubMedCentral

98.

Burnier, J. V., Wang, N., Michel, R. P., Hassanain, M., Li, S., Lu, Y., et al. (2011). Type IV collagen-initiated signals provide survival and growth cues required for liver metastasis. Oncogene, 30(35), 3766–3783. https://doi.org/10.1038/onc.2011.89CrossRefPubMed

99.

Nystrom, H., Tavelin, B., Bjorklund, M., Naredi, P., & Sund, M. (2015). Improved tumour marker sensitivity in detecting colorectal liver metastases by combined type IV collagen and CEA measurement. Tumour Biology, 36(12), 9839–9847. https://doi.org/10.1007/s13277-015-3729-zCrossRefPubMed

100.

Shen, Y., Wang, X., Lu, J., Salfenmoser, M., Wirsik, N. M., Schleussner, N., et al. (2020). Reduction of liver metastasis stiffness improves response to bevacizumab in metastatic colorectal cancer. Cancer Cell, 37(6), 800–817. https://doi.org/10.1016/j.ccell.2020.05.005CrossRefPubMed

101.

Liu, L., Mayes, P. A., Eastman, S., Shi, H., Yadavilli, S., Zhang, T., et al. (2015). The BRAF and MEK inhibitors dabrafenib and trametinib: Effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4. Clinical Cancer Research, 21(7), 1639–1651. https://doi.org/10.1158/1078-0432.CCR-14-2339CrossRefPubMed

102.

Pfirschke, C., Engblom, C., Rickelt, S., Cortez-Retamozo, V., Garris, C., Pucci, F., et al. (2016). Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy. Immunity, 44(2), 343–354. https://doi.org/10.1016/j.immuni.2015.11.024CrossRefPubMedPubMedCentral

103.

Zhang, L., Zhu, Z., Yan, H., Wang, W., Wu, Z., Zhang, F., et al. (2021). Creatine promotes cancer metastasis through activation of Smad2/3. Cell Metabolism, 33(6), 1111–1123. https://doi.org/10.1016/j.cmet.2021.03.009CrossRefPubMed

104.

Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., et al. (2017). Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science, 357(6349), 409–413. https://doi.org/10.1126/science.aan6733CrossRefPubMedPubMedCentral

105.

Ebert, P. J. R., Cheung, J., Yang, Y., McNamara, E., Hong, R., Moskalenko, M., et al. (2016). MAP kinase inhibition promotes T cell and anti-tumor activity in combination with PD-L1 checkpoint blockade. Immunity, 44(3), 609–621. https://doi.org/10.1016/j.immuni.2016.01.024CrossRefPubMed

106.

Hodi, F. S., Lawrence, D., Lezcano, C., Wu, X., Zhou, J., Sasada, T., et al. (2014). Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunology Research, 2(7), 632–642. https://doi.org/10.1158/2326-6066.CIR-14-0053CrossRefPubMedPubMedCentral

Titel: Colorectal cancer liver metastasis: genomic evolution and crosstalk with the liver microenvironment
verfasst von: Qiu-Luo Liu
Huijie Zhou
Zong-Guang Zhou
Hai-Ning Chen
Publikationsdatum: 15.04.2023
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 2/2023
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-023-10107-0

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Colorectal cancer liver metastasis: genomic evolution and crosstalk with the liver microenvironment

Abstract

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2023

Kenneth V. Honn, Ph.D. (1946–2023)

Combination of immune-checkpoint inhibitors and targeted therapies for melanoma therapy: The more, the better?

Considerations for modelling diffuse high-grade gliomas and developing clinically relevant therapies

Epigenetic markers and therapeutic targets for metastasis

Oncogenic super-enhancers in cancer: mechanisms and therapeutic targets

Oncohistones and disrupted development in pediatric-type diffuse high-grade glioma

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie